$DFTX

Definium Therapeutics (NASDAQ:DFTX) reported Q2 results and discussed Phase II GAD data for DT120, saying efficacy was seen by week one and remained significant through week 12, with improvements on secondary endpoints and favorable tolerability. It said VOYAGE and PANORAMA were re-estimated to exceed 99% power. Net loss was $159M, including $86.2M non-cash warrant fair-value expense. The company raised about $758M net in June and had about $1.1B cash to fund operations into 2030.

Definium Therapeutics (NASDAQ: DFTX) reported Q2 2026 results and Phase 3 updates for DT120 ODT. It said Phase 3 Emerge in major depressive disorder met primary and key secondary endpoints, with placebo-adjusted MADRS improvements of 8.1 points at Week 6 and 7.3 at Week 12. Voyage and Panorama topline data are expected Aug 10 and Sept 2026. Cash, cash equivalents and investments were about $1.1B as of June 30, 2026, after a $805M gross public offering.

Definium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dftx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Announced positive topline results from Phase 3 Emerge study of DT120 ODT in major depressive disorder (MDD), demonstrating rapid, robu

Meridian Small Cap Growth Fund’s Q2 2026 investor letter, managed by ArrowMark Partners, reported a 21.54% return for the quarter ended June 30, 2026, versus 25.71% for the Russell 2000 Growth Index. The letter highlighted Definium Therapeutics (NASDAQ:DFTX), noting its Phase 3 major depressive disorder topline results and a share price of $42.16 on July 29, 2026.

PwC estimates over $300 billion in branded pharma revenue will lose patent exclusivity by decade end, driving large drugmakers to buy pipelines. ALPS Advisors says biopharma deal value could exceed $250B in 2026. The ALPS Medical Breakthroughs ETF (SBIO) added 37 names in June; it holds ABBV’s $10.9B Apogee deal target APGE and Definium (DFTX).

The article says the AdvisorShares Psychedelics ETF rose 31% over the past year, outpacing the Nasdaq and S&P 500. It cites optimism from Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary and notes J&J’s Spravato sales exceeded $1B in 2024, projected to reach $3B by 2027-28. It lists analyst-favored psychedelic stocks, including Definium Therapeutics (DFTX) and COMPASS Pathways (CMPS), with stated price-target upside of 28.15% and 38.57%.

Definium Therapeutics (DFTX) rose 3.0% to $45.79 after Stifel issued a bullish note, doubling its price target to $60 from $30 and keeping a Buy rating. Stifel cited stronger-than-expected Phase 3 data for DT120 in major depressive disorder, lowering risk and projecting peak revenues over $4B, with next inflection from Phase 3 GAD topline data.

Definium Therapeutics said it granted inducement stock options to eight newly hired non-executive employees for an aggregate 169,740 common shares, with grant dates of July 6, 2026. The exercise price equals the grant-date closing price, and options vest over four years (25% after one year, then monthly). Approved June 25, 2026 under Nasdaq Rule 5635(c)(4).

In June, the ALPS Medical Breakthroughs ETF (SBIO) returned 18.7%, its best month since Dec 2023, according to VettaFi. Apogee Therapeutics (APGE) added 2.18 pts after AbbVie (ABBV) agreed to acquire it for about $10.9B ($135.11/share). Definium (DFTX) added 1.58 pts after a Phase 3 MDD readout; other movers included Oruka (ORKA).

Sullivan Mark (Chief Legal Officer) sold 13,008 shares of Definium Therapeutics, Inc. (DFTX) at $45.03 ($0.59M total) on 2026-06-25 under a Rule 10b5-1 trading plan.